4482 results about "Constipation" patented technology

The present invention provides food bars for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant containing one or more vitamins and / or minerals, DHA, one or more DHA taste-masking agents and, optionally, one or more anti-constipation and regularity-maintaining agents, methods for preparing these food bars, and methods for supplementing the dietary requirements of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant. The food bars of the invention generally comprise one or more vitamins and minerals recommended for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant in an amount that is effective for enhancing the nutrition of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant, and that is not harmful to developing fetuses or breast-feeding babies, including calcium in an amount above 1,000 mg, DHA in an amount that is effective for providing, or increasing the supply of, DHA to a developing fetus or baby through a placenta or breast milk, one or more DHA taste-masking agents in an amount that is effective for masking the taste of DHA, and that is not harmful to developing fetuses or breast-feeding babies and, optionally, one or more anti-constipation and regularity-maintaining agents in an amount that is effective for reducing or eliminating constipation, and that is not harmful to developing fetuses or breast-feeding babies, from about 0 to about 99 weight percent of carbohydrates, from about 0 to about 80 weight percent of proteins, and from about 0 to about 60 weight percent of fats.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.